Back to top
more

SpringWorks Therapeutics (SWTX)

(Delayed Data from NSDQ)

$38.04 USD

38.04
515,590

+1.17 (3.17%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $38.00 -0.04 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for SWTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for SpringWorks Therapeutics falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 479 592 374 508 328
Receivables 6 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 3 0 0 0 0
Other Current Assets 13 8 9 5 4
Total Current Assets 501 600 383 513 331
Net Property & Equipment 18 14 3 1 1
Investments & Advances 185 9 62 57 1
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 15 3 3 3 2
Total Assets 726 630 452 576 335
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 7 8 3 1 3
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 66 39 25 15 9
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 4 3 0 0 0
Total Current Liabilities 78 51 30 18 12
Mortgages 0 0 0 0 0
Deferred Taxes/Income 15 16 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 100 72 30 19 13
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,524 1,130 715 676 395
Retained Earnings -895 -570 -293 -119 -73
Other Equity 1 -1 0 0 0
Treasury Stock 4 1 0 0 0
Total Shareholder's Equity 626 558 422 557 322
Total Liabilities & Shareholder's Equity 726 630 452 576 335
Total Common Equity 626 558 422 557 322
Shares Outstanding 62.50 62.30 49.20 48.70 43.00
Book Value Per Share 10.02 8.96 8.59 11.44 7.49

Fiscal Year End for SpringWorks Therapeutics falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 437 479 422 477
Receivables NA 16 6 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 5 3 0 0
Other Current Assets NA 14 13 10 7
Total Current Assets NA 472 501 432 484
Net Property & Equipment NA 18 18 21 18
Investments & Advances NA 146 185 4 5
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 15 15 4 4
Total Assets NA 657 726 468 517
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 7 7 6 3
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 56 66 40 35
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 5 4 3 2
Total Current Liabilities NA 69 78 50 42
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 15 15 16 17
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 89 100 73 66
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,561 1,524 1,200 1,177
Retained Earnings NA -982 -895 -801 -721
Other Equity NA 0 1 0 0
Treasury Stock NA 11 4 4 4
Total Shareholder's Equity NA 567 626 395 451
Total Liabilities & Shareholder's Equity NA 657 726 468 517
Total Common Equity 0 567 626 395 451
Shares Outstanding 74.00 74.00 62.50 62.50 62.50
Book Value Per Share 0.00 7.67 10.02 6.32 7.22